All T Cells articles
-
NewsPim1 kinase identified as therapeutic target for inflammatory arthritis
Researchers have identified Pim1 kinase as a critical driver of inflammatory arthritis through its regulation of Th17 cell differentiation via mitochondrial metabolism.
-
ArticleFlow-based human tumour models reveal immune responses missed by static culture
Static cultures may not tell the whole story when it comes to immunotherapy performance. Results from the Mera™ flow-based human tissue model show stronger T-cell activity and cytokine responses under physiological flow, highlighting the role of dynamic immune–tumour interactions in preclinical testing.
-
NewsCytokine-armoured CAR T cells target glioblastoma while reducing treatment toxicity
UCLA Health researchers have developed cytokine-armoured CAR T cells that directly attack glioblastoma tumours whilst recruiting the body’s wider immune system. The engineered cells showed improved tumour control in mouse models and could address antigen heterogeneity challenges that have limited CAR T therapy success in solid tumours.
-
NewsRadiotherapy boosts CAR T cell survival in solid tumours
Mount Sinai researchers have discovered that focused irradiation significantly enhances CAR T cell therapy effectiveness in solid tumours by promoting dendritic cell-mediated antigen presentation, enabling sustained immune cell expansion within the tumour microenvironment whilst minimising off-target toxicity.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
NewsNew imaging reveals how immune cells destroy cancer
Cryo-expansion microscopy has enabled researchers to visualise the three-dimensional organisation of cytotoxic T lymphocytes destroying cancer cells in their near-native state, revealing nanoscale structural details of the immune synapse and cytotoxic granules that could refine immuno-oncology therapeutic strategies.
-
NewsCircio and Acuitas partner on circular RNA CAR T therapy
Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T cell therapy. The collaboration will combine Circio’s technology, which reportedly delivers gene expression lasting up to six months in lymphocytes, with Acuitas’ lipid nanoparticle delivery system targeting specific T cell populations for potential applications in oncology and autoimmune diseases.
-
WebinarManufacturing the Future: from N=1 personalised CRISPR therapy to scalable precision genomic medicine
How biotech leaders are turning one-off CRISPR breakthroughs into scalable, regulatory-ready therapies.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
NewsHaem signalling pathway identified as key driver of T cell exhaustion
University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.
-
NewsScientists develop cream that triggers skin’s anti-cancer defence
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.
-
ArticleMaking immunotherapy safer and more accessible through continuous digital monitoring
Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome continues to restrict access. This article explores how continuous digital monitoring and AI-driven analysis could enable safer outpatient delivery and support more scalable immunotherapy adoption.
-
NewsAMD3100 drug could boost immunotherapy in rare liver cancer
A rare liver cancer that primarily affects young people may soon have a new treatment option, after researchers found that an existing FDA-approved drug could enable immunotherapy to work effectively against tumours.
-
NewsHow vaccine structure shapes immune response to HPV tumours
Researchers have discovered that reorganising a single cancer-targeting peptide within a spherical nucleic acid vaccine dramatically boosts the immune system’s ability to attack HPV-driven tumours.
-
NewsEngineered extracellular vesicles control immune responses
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
-
ArticleLogic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
-
NewsAI powers discovery of new CBLB inhibitor ISM3830
Insilico Medicine has announced ISM3830, an AI-designed CBLB inhibitor that has demonstrated promising preclinical results.
-
NewsPre-transplant treg therapy reduces GVHD risk for blood cancer patients
Priming the immune system ahead of a stem cell transplant may be key to safer, more effective care for blood cancer patients, according to new research showing major reductions in transplant complications.
-
NewsWhy TIGIT cancer therapies work in monkeys but not humans
A new study reveals that TIGIT, a key immune checkpoint targeted by cancer drugs, behaves differently in rhesus macaques and humans, suggesting current animal tests may be misleading drug development.
-
NewsNew CAR-T cell therapy capable of destroying glioblastoma cells
A new CAR-T treatment developed in Switzerland has shown striking early success against glioblastoma, one of the deadliest brain cancers, and is now moving towards human trials.